用IL-2/LAK细胞联合治疗81例原发性肝癌,分别采用经静脉输注、肌肉注射及肿瘤局部用药。治疗后作CT、B超检查,观察肿瘤占位、淋巴细胞亚群、肝功能及临床症状、体征改变等。结果表明,局部用药组总有效率显著高于其他各组(P<0.01)。T细胞亚群检测表明,各治疗组治疗后的细胞免疫水平均显著提高。 Eighty-one patients with primary liver cancer were treated with IL-2/LAK cells and were treated with intravenous infusion, intramuscular injection, and topical use of the tumor. After treatment, CT and B-ultrasound examinations were performed to observe the tumor occupying position, lymphocyte subsets, liver function, and clinical symptoms and signs changes. The results showed that the total effective rate of topical medication group was significantly higher than that of other groups (P<0.01). T-cell subpopulations showed significant improvement in cellular immune levels after treatment in each treatment group.